Cargando…
Monitoring the Early Response of Fulvestrant Plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal (18)F-FES PET/CT
Endocrine monotherapy of breast cancers is generally hampered by the primary/acquired resistance and adverse sides in clinical settings. Herein, advantaging the multitargeting antitumor effects and normal organ-protecting roles of Chinese herbal medicine, the aim of this study was to investigate the...
Autores principales: | He, SiMin, Wang, MingWei, Zhang, YongPing, Luo, JianMin, Zhang, YingJian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590558/ https://www.ncbi.nlm.nih.gov/pubmed/31281233 http://dx.doi.org/10.1155/2019/2374565 |
Ejemplares similares
-
Comparison of (18)F-FES, (18)F-FDG, and (18)F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer
por: He, SiMin, et al.
Publicado: (2016) -
A preliminary study of (18)F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel
por: Gong, Chengcheng, et al.
Publicado: (2017) -
The Molecular Mechanisms of Tanshinone IIA on the Apoptosis and Arrest of Human Esophageal Carcinoma Cells
por: Wang, Jiang-Feng, et al.
Publicado: (2014) -
Effect of Supplementation of Tanshinone IIA and Sodium Tanshinone IIA Sulfonate on the Anticancer Effect of Epirubicin: An In Vitro Study
por: Chan, Szu-Erh, et al.
Publicado: (2011) -
Analyzing the Estrogen Receptor Status of Liver Metastases with [(18)F]-FES-PET in Patients with Breast Cancer
por: Boers, Jorianne, et al.
Publicado: (2021)